Tumor markers in ovarian carcinoma (Q36767181)

16 August 2017

1 reference

title

Tumor markers in ovarian carcinoma (English)

1 reference

16 August 2017

M R Raspollini

1

1 reference

16 August 2017

G L Taddei

series ordinal

2

1 reference

16 August 2017

publication date

26 March 2007

1 reference

International Journal of Gynecology and Obstetrics

16 August 2017

published in

1 reference

16 August 2017

volume

97

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

175-181

1 reference

Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Diverse tumorigenic pathways in ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Antiangiogenic and antivascular therapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Antiangiogenic chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Multidrug resistance (mdr) genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Salvage Chemotherapy for Refractory Transitional Cell Carcinoma of the Ovary (TCC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2007.02.011

10.1016/J.IJGO.2007.02.011

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference